Angiotensin-convertingenzyme (ACE) inhibitors are amongthe most widely prescribed antihypertensive agents in the UnitedStates, but when used in the second half of pregnancy, theycan cause oligohydramnios, fetal growth retardation, pulmonaryhypoplasia, joint contractures, hypocalvaria and neonatal renalfailure, hypotension, and death.1,2,3 These effects result fromblockade of the conversion of angiotensin I to angiotensin IIin the developing fetal kidneys.3 A strikingly similar patternof fetal anomalies has been reported after treatment of womenin the second or third trimester of pregnancy with angiotensinIIreceptor antagonists,1,4 drugs that block the fetalreninangiotensin system at a different point.
From the Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
This article has been cited by other articles:
Murphy, H. R, Temple, R. C, Roland, J. M
(2007). Improving outcomes of pregnancy for women with type 1 and type 2 diabetes. British Journal of Diabetes & Vascular Disease
7: 38-42
[Abstract]
(2006). ACE Inhibitors and Birth Defects: Unsafe in Any Trimester. JWatch Women's Health
2006: 1-1
[Full Text]
(2006). ACE Inhibitors Are Teratogenic in the First Trimester. Journal Watch Cardiology
2006: 1-1
[Full Text]
(2006). Safety of First-Trimester Exposure to ACE Inhibitors. JWatch General
2006: 3-3
[Full Text]